The human gastrointestinal tract and oral microbiota in inflammatory bowel disease: a state of the science review

López, Rosario Lucas; Grande, María José López; Galvez, A. Fernandez; Pulido, Rubén Pérez

doi:10.1111/apm.12609

Cited by 102 publications

(66 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ulcerative colitis is a well‐described clinical disease with an ill‐defined aetiology and remains very challenging to treat. Once triggered in genetically susceptible individuals, an impaired immune response develops, leading to a lack of tolerance to the resident gut microbiota (Lucas Lopez, Grande Burgos, Galvez, & Perez Pulido, ; Thompson‐Chagoyan, Maldonado, & Gil, ; Zhang et al., ). The gut bacteriome is not yet clearly defined, and neither is the mycobiome or virome (Clavel, Lagkouvardos, & Hiergeist, ; Gupta et al., ; Nash et al., ; Virgin, ; Zhang et al., ).…”

Section: Discussionmentioning

confidence: 99%

World Workshop on Oral Medicine VII: Targeting the oral microbiome Part 2: Current knowledge on malignant and potentially malignant oral disorders

et al. 2019

View full text Add to dashboard Cite

Objective The World Workshop on Oral Medicine VII chose the oral microbiome as a focus area. Part 1 presents the methodological state of the science for oral microbiome studies. Part 2 was guided by the question: What is currently known about the microbiome associated with oral squamous cell carcinoma and potentially malignant disorders of the oral mucosa? Materials and Methods A scoping review methodology was followed to identify and analyse relevant studies on the composition and potential functions of the oral microbiota using high‐throughput sequencing techniques. The authors performed searches in PubMed and EMBASE. After removal of duplicates, a total of 239 potentially studies were identified. Results Twenty‐three studies on oral squamous cell carcinoma, two on oral leukoplakia and four on oral lichen planus were included with substantial differences in diagnostic criteria, sample type, region sequenced and sequencing method utilised. The majority of studies focused on bacterial identification and recorded statistically significant differences in the oral microbiota associated with health and disease. However, even when comparing studies of similar methodology, the microbial differences between health and disease varied considerably. No consensus on the composition of the microbiomes associated with these conditions on genus and species level could be obtained. Six studies on oral squamous cell carcinoma had included in silico predicted microbial functions (genes and/or pathways) and found some similarities between the studies. Conclusions Attempts to reveal the microbiome associated with oral mucosal diseases are still in its infancy, and the studies demonstrate significant clinical and methodological heterogeneity across disease categories. The immense richness and diversity of the microbiota clearly illustrate that there is a need for additional methodologically comparable studies utilising deep sequencing approaches in significant cohorts of subjects together with functional analyses. Our hope is that following the recipe as outlined in our preceding companion paper, that is Part 1, will enhance achieving this in the future and elucidate the role of the oral microbiome in oral squamous cell carcinoma and potentially malignant disorders of the oral mucosa.

show abstract

Section: Discussionmentioning

confidence: 99%

World Workshop on Oral Medicine VII: Targeting the oral microbiome Part 2: Current knowledge on malignant and potentially malignant oral disorders

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Epidemiological studies have shown that the composition of the intestinal bacterial microbiota can correlate with the development of, or resistance to, obesity (25), malnutrition (26, 27), and allergic disease (28) and may also influence cognitive function and development (29). The intestinal microbiota is not limited to prokaryotes (30), with archaea and eukaryotes potentially contributing to clinical variation (31, 32). …”

Section: Intestinal Microbiotamentioning

confidence: 99%

Parasitic Protozoa and Interactions with the Host Intestinal Microbiota

et al. 2017

View full text Add to dashboard Cite

Parasitic protozoan infections represent a major health burden in the developing world and contribute significantly to morbidity and mortality. These infections are often associated with considerable variability in clinical presentation. An emerging body of work suggests that the intestinal microbiota may help to explain some of these differences in disease expression. The objective of this minireview is to synthesize recent progress in this rapidly advancing field. Studies of humans and animals and in vitro studies of the contribution of the intestinal microbiota to infectious disease are discussed. We hope to provide an understanding of the human-protozoal pathogen-microbiome interaction and to speculate on how that might be leveraged for treatment.

show abstract

“…Bacterial microflora can also participate in the pathogenesis of ulcerative colitis in humans [45][46][47]. Interestingly, a large number of previous studies indicated that H. perforatum extracts, especially alcoholic ones had remarkable anti-bacterial properties [48].…”

Section: Gross Appearance Of the Colonic Mucosa In Experimental Groupsmentioning

confidence: 99%

The Beneficial Effects of Hypiran in Ameliorating Rat Model of Ulcerative Colitis

Froushani

Mashouri

2018

Zahedan J Res Med Sci

View full text Add to dashboard Cite

Background: Different studies have been done on Hypericum anti-depressant effects, but only a few ones have documented in vivo anti-inflammatory properties of Hypericum following systemic administration. Objectives: This survey was designed to evaluate the potential effects of Hypiran, a hydro-alcoholic extract of St. John's Wort, for the treatment and controlling inflammation in animal models of ulcerative colitis. Methods: In this experimental study, ulcerative colitis was induced in the male Wistar rats by luminal instillation of acetic acid. Animals in the treatment groups received Hypiran (150 mg/kg PO) or Prednisolone (4 mg/kg PO) daily for 10 consecutive days. At the end, the rats were sacrificed and the disease activity index, the levels of malondialdehyde, myeloperoxidase, nitric oxide, total protein and the concentration of TNF-α, IL-1β and IL-6 were assessed in the colonic homogenized tissue specimens. Results:The results showed that both therapies with Hypiran and Prednisolone could regress the clinical scores and the mortality rate of ulcerative colitis in a comparable manner. The levels of TNF-α, IL-1β and myeloperoxidase activity were down-regulated in the guts of Prednisolone treated rats more than Hypiran groups. Nevertheless, Hypiran decreased the levels of IL-6, nitric oxide and malondialdehyde more significantly than Prednisolone. Conclusions: Collectively, these data suggest that the Hypiran may be used as a natural source to alleviate the signs of rat model of ulcerative colitis.

show abstract

The human gastrointestinal tract and oral microbiota in inflammatory bowel disease: a state of the science review

Cited by 102 publications

References 82 publications

World Workshop on Oral Medicine VII: Targeting the oral microbiome Part 2: Current knowledge on malignant and potentially malignant oral disorders

World Workshop on Oral Medicine VII: Targeting the oral microbiome Part 2: Current knowledge on malignant and potentially malignant oral disorders

Parasitic Protozoa and Interactions with the Host Intestinal Microbiota

The Beneficial Effects of Hypiran in Ameliorating Rat Model of Ulcerative Colitis

Contact Info

Product

Resources

About